Loading company
Veru Inc.
VERU · Nasdaq · ·
$2.58+2.0%Sep 29 close
- 1M
- -1.7%
- 6M
- +21.1%
- 1Y
- -32.1%
- 5Y
- -97.2%
VERU · Nasdaq · ·
$2.58+2.0%Sep 29 close
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toMar 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $4.1M | -100.00% |
| Profit | -$7M | -$7.3M | +4.70% |
| Profit per share | -$0.07 | -$0.42 | +83.33% |
| Free Cash Flow | -$5.5M | -$5.5M | +0.27% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Veru Inc. has no earnings call transcript available.
“We are extremely pleased with the continued enobosarm progress during this past quarter,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass to improve body composition and physical function which is expected to result in clinically meaningful incremental weight reduction versus GLP-1 RA therapy alone. Sabizabulin, a microtubule disruptor, is being developed for the treatment of chronic inflammation related to atherosclerotic cardiovascular disease.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Veru Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.